;PMID: 11510629
;source_file_1896.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..117] = [t:44..117]
;2)section:[e:121..171] = [t:121..171]
;3)section:[e:175..245] = [t:175..245]
;4)sentence:[e:249..422] = [t:249..422]
;5)sentence:[e:423..560] = [t:423..560]
;6)sentence:[e:562..653] = [t:562..653]
;7)sentence:[e:654..850] = [t:654..850]
;8)sentence:[e:851..998] = [t:851..998]
;9)sentence:[e:999..1146] = [t:999..1146]
;10)sentence:[e:1147..1307] = [t:1147..1307]
;11)sentence:[e:1308..1406] = [t:1308..1406]
;12)sentence:[e:1407..1662] = [t:1407..1662]
;13)sentence:[e:1663..1786] = [t:1663..1786]
;14)sentence:[e:1787..1900] = [t:1787..1900]
;15)sentence:[e:1902..2000] = [t:1902..2000]
;16)sentence:[e:2001..2139] = [t:2001..2139]
;17)section:[e:2143..2161] = [t:2143..2161]
;18)section:[e:2167..2173] = [t:2167..2173]
;19)section:[e:2179..2195] = [t:2179..2195]
;20)section:[e:2199..2244] = [t:2199..2244]

;section 0 Span:0..38
;Clin Pharmacokinet. 2001;40(7):523-37.
(SEC
  (FRAG (NNP:[0..4] Clin) (NNP:[5..18] Pharmacokinet) (.:[18..19] .)
        (CD:[20..24] 2001) (CC:[24..27] ;40) (-LRB-:[27..28] -LRB-)
        (CD:[28..29] 7) (-RRB-:[29..30] -RRB-) (::[30..31] :)
        (CD:[31..37] 523-37) (.:[37..38] .)))

;sentence 1 Span:44..117
;Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole.
;[44..48]:substance:"Drug"
;[74..86]:substance:"esomeprazole"
;[92..102]:substance:"(S)-isomer"
;[106..116]:substance:"omeprazole"
(SENT
  (NP-HLN
    (NP
      (NML (NN:[44..48] Drug) (NN:[49..60] interaction))
      (NNS:[61..68] studies))
    (PP (IN:[69..73] with)
      (NP
        (NP (NN:[74..86] esomeprazole))
        (,:[86..87] ,)
        (NP
          (NP (DT:[88..91] the) (NN:[92..102] -LRB-S-RRB--isomer))
          (PP (IN:[103..105] of)
            (NP (NN:[106..116] omeprazole))))))
    (.:[116..117] .)))

;section 2 Span:121..171
;Andersson T, Hassan-Alin M, Hasselgren G, Rohss K.
(SEC
  (FRAG (NNP:[121..130] Andersson) (NNP:[131..132] T) (,:[132..133] ,)
        (NNP:[134..140] Hassan) (HYPH:[140..141] -) (NNP:[141..145] Alin)
        (NNP:[146..148] M,) (NNP:[149..159] Hasselgren) (NNP:[160..161] G)
        (,:[161..162] ,) (NNP:[163..168] Rohss) (NNP:[169..171] K.)))

;section 3 Span:175..245
;Clinical Pharmacology, AstraZeneca LP, Wayne, Pennsylvania 19087, USA.
(SEC
  (FRAG (NNP:[175..183] Clinical) (NNP:[184..196] Pharmacology) (,:[196..197] ,)
        (NNP:[198..209] AstraZeneca) (NNP:[210..212] LP) (,:[212..213] ,)
        (NNP:[214..219] Wayne) (,:[219..220] ,) (NNP:[221..233] Pennsylvania)
        (CD:[234..239] 19087) (,:[239..240] ,) (NNP:[241..244] USA)
        (.:[244..245] .)))

;sentence 4 Span:249..422
;Esomeprazole, the (S)-isomer of omeprazole, is the first proton pump
;inhibitor  (PPI) developed as a single isomer for the treatment of patients
;with acid  related diseases.
;[249..261]:substance:"Esomeprazole"
;[267..277]:substance:"(S)-isomer"
;[281..291]:substance:"omeprazole"
;[306..327]:substance:"proton pump inhibitor"
;[330..333]:substance:"PPI"
;[357..363]:substance:"isomer"
;[399..403]:substance:"acid"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[249..261] Esomeprazole))
      (,:[261..262] ,)
      (NP
        (NP (DT:[263..266] the) (NN:[267..277] -LRB-S-RRB--isomer))
        (PP (IN:[278..280] of)
          (NP (NN:[281..291] omeprazole)))))
    (,:[291..292] ,)
    (VP (VBZ:[293..295] is)
      (NP-PRD
        (NP
          (NP (DT:[296..299] the) (JJ:[300..305] first)
            
            (NML (NN:[306..312] proton) (NN:[313..317] pump))
            (NN:[318..327] inhibitor))
          (NP (-LRB-:[329..330] -LRB-) (NN:[330..333] PPI)
              (-RRB-:[333..334] -RRB-)))
        (VP (VBN:[335..344] developed)
          (NP (-NONE-:[344..344] *))
          (PP (IN:[345..347] as)
            (NP (DT:[348..349] a) (JJ:[350..356] single) (NN:[357..363] isomer)))
          (PP-PRP (IN:[364..367] for)
            (NP
              (NP (DT:[368..371] the) (NN:[372..381] treatment))
              (PP (IN:[382..384] of)
                (NP
                  (NP (NNS:[385..393] patients))
                  (PP (IN:[394..398] with)
                    (NP
                      (ADJP (NN:[399..403] acid) (VBN:[405..412] related))
                      (NNS:[413..421] diseases))))))))))
    (.:[421..422] .)))

;sentence 5 Span:423..560
;Because of the extensive use of PPIs, the documentation of the  potential for
;drug interactions with esomeprazole is of great importance.
;[455..459]:substance:"PPIs"
;[501..505]:substance:"drug"
;[524..536]:substance:"esomeprazole"
(SENT
  (S
    (PP (IN:[423..430] Because) (IN:[431..433] of)
      (NP
        (NP (DT:[434..437] the) (JJ:[438..447] extensive) (NN:[448..451] use))
        (PP (IN:[452..454] of)
          (NP (NNS:[455..459] PPIs)))))
    (,:[459..460] ,)
    (NP-SBJ
      (NP (DT:[461..464] the) (NN:[465..478] documentation))
      (PP (IN:[479..481] of)
        (NP
          (NP (DT:[482..485] the) (NN:[487..496] potential))
          (PP (IN:[497..500] for)
            (NP
              (NP (NN:[501..505] drug) (NNS:[506..518] interactions))
              (PP (IN:[519..523] with)
                (NP (NN:[524..536] esomeprazole))))))))
    (VP (VBZ:[537..539] is)
      (PP-PRD (IN:[540..542] of)
        (NP (JJ:[543..548] great) (NN:[549..559] importance))))
    (.:[559..560] .)))

;sentence 6 Span:562..653
;Altered absorption or metabolism are 2 of the major mechanisms for drug-drug 
;interactions.
;[629..633]:substance:"drug"
;[634..638]:substance:"drug"
(SENT
  (S
    (NP-SBJ
      (NP
        (ADJP-1 (VBN:[562..569] Altered))
        (NN:[570..580] absorption))
      (CC:[581..583] or)
      (NP
        (ADJP-1 (-NONE-:[583..583] *P*))
        (NN:[584..594] metabolism)))
    (VP (VBP:[595..598] are)
      (NP-PRD
        (NP (CD:[599..600] 2))
        (PP (IN:[601..603] of)
          (NP
            (NP (DT:[604..607] the) (JJ:[608..613] major)
                (NNS:[614..624] mechanisms))
            (PP (IN:[625..628] for)
              (NP
                (NML (NN:[629..633] drug) (HYPH:[633..634] -)
                     (NN:[634..638] drug))
                (NNS:[640..652] interactions)))))))
    (.:[652..653] .)))

;sentence 7 Span:654..850
;Since intragastric pH will increase with esomeprazole treatment,  it can be
;hypothesised that the absorption of drugs with pH-sensitive absorption  (e.g.
;digoxin and ketoconazole) may be affected.
;[695..707]:substance:"esomeprazole"
;[766..771]:substance:"drugs"
;[808..815]:substance:"digoxin"
;[820..832]:substance:"ketoconazole"
(SENT
  (S
    (SBAR-ADV (IN:[654..659] Since)
      (S
        (NP-SBJ (JJ:[660..672] intragastric) (NN:[673..675] pH))
        (VP (MD:[676..680] will)
          (VP (VB:[681..689] increase)
            (PP (IN:[690..694] with)
              (NP (NN:[695..707] esomeprazole) (NN:[708..717] treatment)))))))
    (,:[717..718] ,)
    (NP-SBJ-2
      (NP (PRP:[720..722] it))
      (SBAR-3 (-NONE-:[722..722] *EXP*)))
    (VP (MD:[723..726] can)
      (VP (VB:[727..729] be)
        (VP (VBN:[730..742] hypothesised)
          (NP-2 (-NONE-:[742..742] *))
          (SBAR-3 (IN:[743..747] that)
            (S
              (NP-SBJ-1
                (NP (DT:[748..751] the) (NN:[752..762] absorption))
                (PP (IN:[763..765] of)
                  (NP
                    (NP (NNS:[766..771] drugs))
                    (PP (IN:[772..776] with)
                      (NP
                        (ADJP (NN:[777..779] pH) (HYPH:[779..780] -)
                              (JJ:[780..789] sensitive))
                        (NN:[790..800] absorption)))
                    (PRN (-LRB-:[802..803] -LRB-)
                      (NP
                        (ADVP (FW:[803..807] e.g.))
                        (NN:[808..815] digoxin) (CC:[816..819] and)
                         (NN:[820..832] ketoconazole))
                      (-RRB-:[832..833] -RRB-)))))
              (VP (MD:[834..837] may)
                (VP (VB:[838..840] be)
                  (VP (VBN:[841..849] affected)
                    (NP-1 (-NONE-:[849..849] *))))))))))
    (.:[849..850] .)))

;sentence 8 Span:851..998
;Esomeprazole does not seem to  have any potential to interact with drugs that
;are metabolised by cytochrome  P450 (CYP) 1 A2, 2A6, 2C9, 2D6 or 2E1.
;[851..863]:substance:"Esomeprazole"
;[918..923]:substance:"drugs"
;[948..975]:cyp450:"cytochrome  P450 (CYP) 1 A2"
;[948..970]...[994..997]:cyp450:"cytochrome  P450 (CYP)"..."2E1"
;[948..970]...[987..990]:cyp450:"cytochrome  P450 (CYP)"..."2D6"
;[948..970]...[982..985]:cyp450:"cytochrome  P450 (CYP)"..."2C9"
;[948..970]...[977..980]:cyp450:"cytochrome  P450 (CYP)"..."2A6"
(SENT
  (S
    (NP-SBJ-4 (NN:[851..863] Esomeprazole))
    (VP (VBZ:[864..868] does) (RB:[869..872] not)
      (VP (VB:[873..877] seem)
        (S
          (NP-SBJ-4 (-NONE-:[877..877] *))
          (VP (TO:[878..880] to)
            (VP (VB:[882..886] have)
              (NP (DT:[887..890] any) (NN:[891..900] potential)
                (S
                  (NP-SBJ (-NONE-:[900..900] *))
                  (VP (TO:[901..903] to)
                    (VP (VB:[904..912] interact)
                      (PP-CLR (IN:[913..917] with)
                        (NP
                          (NP (NNS:[918..923] drugs))
                          (SBAR
                            (WHNP-2 (WDT:[924..928] that))
                            (S
                              (NP-SBJ-2 (-NONE-:[928..928] *T*))
                              (VP (VBP:[929..932] are)
                                (VP (VBN:[933..944] metabolised)
                                  (NP-2 (-NONE-:[944..944] *))
                                  (PP (IN:[945..947] by)
                                    (NP-LGS
                                      (NP
                                        (NML-1
                                          (NML (NN:[948..958] cytochrome)
                                               (NN:[960..964] P450))
                                          (NML (-LRB-:[965..966] -LRB-)
                                               (NN:[966..969] CYP)
                                               (-RRB-:[969..970] -RRB-)))
                                        (CD:[971..972] 1) (NN:[973..975] A2))
                                      (,:[975..976] ,)
                                      (NP
                                        (NML-1 (-NONE-:[976..976] *P*))
                                        (NN:[977..980] 2A6))
                                      (,:[980..981] ,)
                                      (NP
                                        (NML-1 (-NONE-:[981..981] *P*))
                                        (NN:[982..985] 2C9))
                                      (,:[985..986] ,)
                                      (NP
                                        (NML-1 (-NONE-:[986..986] *P*))
                                        (NN:[987..990] 2D6))
                                      (CC:[991..993] or)
                                      (NP
                                        (NML-1 (-NONE-:[993..993] *P*))
                                        (NN:[994..997] 2E1)))))))))))))))))))
    (.:[997..998] .)))

;sentence 9 Span:999..1146
;In drug interaction studies with  diazepam, phenytoin and (R)-warfarin, it
;was shown that esomeprazole has the  potential to interact with CYP2C19.
;[1002..1006]:substance:"drug"
;[1033..1041]:substance:"diazepam"
;[1043..1052]:substance:"phenytoin"
;[1057..1069]:substance:"(R)-warfarin"
;[1089..1101]:substance:"esomeprazole"
;[1138..1145]:cyp450:"CYP2C19"
(SENT
  (S
    (PP-LOC (IN:[999..1001] In)
      (NP
        (NP
          (NML (NN:[1002..1006] drug) (NN:[1007..1018] interaction))
          (NNS:[1019..1026] studies))
        (PP (IN:[1027..1031] with)
          (NP (NN:[1033..1041] diazepam) (,:[1041..1042] ,)
              (NN:[1043..1052] phenytoin) (CC:[1053..1056] and)
              (NN:[1057..1069] -LRB-R-RRB--warfarin)))))
    (,:[1069..1070] ,)
    (NP-SBJ-2 (PRP:[1071..1073] it))
    (VP (VBD:[1074..1077] was)
      (VP (VBN:[1078..1083] shown)
        (NP-2 (-NONE-:[1083..1083] *))
        (SBAR (IN:[1084..1088] that)
          (S
            (NP-SBJ (NN:[1089..1101] esomeprazole))
            (VP (VBZ:[1102..1105] has)
              (NP (DT:[1106..1109] the) (NN:[1111..1120] potential)
                (S
                  (NP-SBJ (-NONE-:[1120..1120] *))
                  (VP (TO:[1121..1123] to)
                    (VP (VB:[1124..1132] interact)
                      (PP-CLR (IN:[1133..1137] with)
                        (NP (NN:[1138..1145] CYP2C19))))))))))))
    (.:[1145..1146] .)))

;sentence 10 Span:1147..1307
;The slightly altered metabolism of cisapride  was also suggested to be the
;result of inhibition of a minor metabolic pathway  for cisapride mediated by
;CYP2C19.
;[1182..1191]:substance:"cisapride"
;[1277..1286]:substance:"cisapride"
;[1299..1306]:cyp450:"CYP2C19"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1147..1150] The)
        (ADJP (RB:[1151..1159] slightly) (VBN:[1160..1167] altered))
        (NN:[1168..1178] metabolism))
      (PP (IN:[1179..1181] of)
        (NP (NN:[1182..1191] cisapride))))
    (VP (VBD:[1193..1196] was)
      (ADVP (RB:[1197..1201] also))
      (VP (VBN:[1202..1211] suggested)
        (S
          (NP-SBJ-1 (-NONE-:[1211..1211] *))
          (VP (TO:[1212..1214] to)
            (VP (VB:[1215..1217] be)
              (NP-PRD
                (NP (DT:[1218..1221] the) (NN:[1222..1228] result))
                (PP (IN:[1229..1231] of)
                  (NP
                    (NP (NN:[1232..1242] inhibition))
                    (PP (IN:[1243..1245] of)
                      (NP
                        (NP
                          (NP (DT:[1246..1247] a) (JJ:[1248..1253] minor)
                              (JJ:[1254..1263] metabolic)
                              (NN:[1264..1271] pathway))
                          (PP (IN:[1273..1276] for)
                            (NP (NN:[1277..1286] cisapride))))
                        (VP (VBN:[1287..1295] mediated)
                          (NP (-NONE-:[1295..1295] *))
                          (PP (IN:[1296..1298] by)
                            (NP-LGS (NN:[1299..1306] CYP2C19))))))))))))))
    (.:[1306..1307] .)))

;sentence 11 Span:1308..1406
;Esomeprazole did not interact with the CYP3A4  substrates clarithromycin (2
;studies) or quinidine.
;[1308..1320]:substance:"Esomeprazole"
;[1347..1353]:cyp450:"CYP3A4"
;[1355..1365]:substance:"substrates"
;[1366..1380]:substance:"clarithromycin"
;[1396..1405]:substance:"quinidine"
(SENT
  (S
    (NP-SBJ (NN:[1308..1320] Esomeprazole))
    (VP (VBD:[1321..1324] did) (RB:[1325..1328] not)
      (VP (VB:[1329..1337] interact)
        (PP-CLR (IN:[1338..1342] with)
          (NP
            (NP (DT:[1343..1346] the) (NN:[1347..1353] CYP3A4)
                (NNS:[1355..1365] substrates))
            (NP
              (NP
                (NP (NN:[1366..1380] clarithromycin))
                (PRN (-LRB-:[1381..1382] -LRB-)
                  (NP (CD:[1382..1383] 2) (NNS:[1384..1391] studies))
                  (-RRB-:[1391..1392] -RRB-)))
              (CC:[1393..1395] or)
              (NP (NN:[1396..1405] quinidine)))))))
    (.:[1405..1406] .)))

;sentence 12 Span:1407..1662
;Since the slightly increased  area under the concentration-time curve (AUC)
;of cisapride could be explained as  an inhibition of CYP2C19, the data on
;these 3 CYP3A4 substrates indicate that  esomeprazole does not have the
;potential to inhibit this enzyme.
;[1486..1495]:substance:"cisapride"
;[1536..1543]:cyp450:"CYP2C19"
;[1565..1571]:cyp450:"CYP3A4"
;[1572..1582]:substance:"substrates"
;[1598..1610]:substance:"esomeprazole"
;[1655..1661]:cyp450:"enzyme"
(SENT
  (S
    (SBAR-ADV (IN:[1407..1412] Since)
      (S
        (NP-SBJ-1
          (NP
            (NP
              (NP (DT:[1413..1416] the)
                (ADJP (RB:[1417..1425] slightly) (VBN:[1426..1435] increased))
                (NN:[1437..1441] area))
              (PP (IN:[1442..1447] under)
                (NP (DT:[1448..1451] the)
                  (NML (NN:[1452..1465] concentration) (HYPH:[1465..1466] -)
                       (NN:[1466..1470] time))
                  (NN:[1471..1476] curve))))
            (NP (-LRB-:[1477..1478] -LRB-) (NN:[1478..1481] AUC)
                (-RRB-:[1481..1482] -RRB-)))
          (PP (IN:[1483..1485] of)
            (NP (NN:[1486..1495] cisapride))))
        (VP (MD:[1496..1501] could)
          (VP (VB:[1502..1504] be)
            (VP (VBN:[1505..1514] explained)
              (NP-1 (-NONE-:[1514..1514] *))
              (PP (IN:[1515..1517] as)
                (NP
                  (NP (DT:[1519..1521] an) (NN:[1522..1532] inhibition))
                  (PP (IN:[1533..1535] of)
                    (NP (NN:[1536..1543] CYP2C19))))))))))
    (,:[1543..1544] ,)
    (NP-SBJ
      (NP (DT:[1545..1548] the) (NNS:[1549..1553] data))
      (PP (IN:[1554..1556] on)
        (NP (DT:[1557..1562] these) (CD:[1563..1564] 3) (NN:[1565..1571] CYP3A4)
            (NNS:[1572..1582] substrates))))
    (VP (VBP:[1583..1591] indicate)
      (SBAR (IN:[1592..1596] that)
        (S
          (NP-SBJ (NN:[1598..1610] esomeprazole))
          (VP (VBZ:[1611..1615] does) (RB:[1616..1619] not)
            (VP (VB:[1620..1624] have)
              (NP (DT:[1625..1628] the) (NN:[1629..1638] potential)
                (S
                  (NP-SBJ (-NONE-:[1638..1638] *))
                  (VP (TO:[1639..1641] to)
                    (VP (VB:[1642..1649] inhibit)
                      (NP (DT:[1650..1654] this) (NN:[1655..1661] enzyme)))))))))))
    (.:[1661..1662] .)))

;sentence 13 Span:1663..1786
;The minor  effects reported for diazepam, phenytoin, (R)-warfarin, and
;cisapride are  unlikely to be of clinical relevance.
;[1695..1703]:substance:"diazepam"
;[1705..1714]:substance:"phenytoin"
;[1716..1728]:substance:"(R)-warfarin"
;[1734..1743]:substance:"cisapride"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1663..1666] The) (JJ:[1667..1672] minor)
          (NNS:[1674..1681] effects))
      (VP (VBN:[1682..1690] reported)
        (NP (-NONE-:[1690..1690] *))
        (PP (IN:[1691..1694] for)
          (NP (NN:[1695..1703] diazepam) (,:[1703..1704] ,)
              (NN:[1705..1714] phenytoin) (,:[1714..1715] ,)
              (NN:[1716..1728] -LRB-R-RRB--warfarin) (,:[1728..1729] ,)
              (CC:[1730..1733] and) (NN:[1734..1743] cisapride)))))
    (VP (VBP:[1744..1747] are)
      (ADJP-PRD (JJ:[1749..1757] unlikely)
        (S
          (NP-SBJ-1 (-NONE-:[1757..1757] *))
          (VP (TO:[1758..1760] to)
            (VP (VB:[1761..1763] be)
              (PP-PRD (IN:[1764..1766] of)
                (NP (JJ:[1767..1775] clinical) (NN:[1776..1785] relevance))))))))
    (.:[1785..1786] .)))

;sentence 14 Span:1787..1900
;Clarithromycin interacts with the  metabolism of esomeprazole resulting in a
;doubling of the AUC of esomeprazole.
;[1787..1801]:substance:"Clarithromycin"
;[1836..1848]:substance:"esomeprazole"
;[1887..1899]:substance:"esomeprazole"
(SENT
  (S
    (NP-SBJ (NN:[1787..1801] Clarithromycin))
    (VP (VBZ:[1802..1811] interacts)
      (PP-CLR (IN:[1812..1816] with)
        (NP
          (NP (DT:[1817..1820] the) (NN:[1822..1832] metabolism))
          (PP (IN:[1833..1835] of)
            (NP (NN:[1836..1848] esomeprazole)))))
      (NP-ADV
        (NP-SBJ (-NONE-:[1848..1848] *))
        (VP (VBG:[1849..1858] resulting)
          (PP-CLR (IN:[1859..1861] in)
            (NP
              (NP (DT:[1862..1863] a) (NN:[1864..1872] doubling))
              (PP (IN:[1873..1875] of)
                (NP
                  (NP (DT:[1876..1879] the) (NN:[1880..1883] AUC))
                  (PP (IN:[1884..1886] of)
                    (NP (NN:[1887..1899] esomeprazole))))))))))
    (.:[1899..1900] .)))

;sentence 15 Span:1902..2000
;The increased plasma concentrations of esomeprazole are unlikely to have any 
;safety implications.
;[1941..1953]:substance:"esomeprazole"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1902..1905] The) (VBN:[1906..1915] increased)
          (NN:[1916..1922] plasma) (NNS:[1923..1937] concentrations))
      (PP (IN:[1938..1940] of)
        (NP (NN:[1941..1953] esomeprazole))))
    (VP (VBP:[1954..1957] are)
      (ADJP-PRD (JJ:[1958..1966] unlikely)
        (S
          (NP-SBJ-1 (-NONE-:[1966..1966] *))
          (VP (TO:[1967..1969] to)
            (VP (VB:[1970..1974] have)
              (NP (DT:[1975..1978] any) (NN:[1980..1986] safety)
                  (NNS:[1987..1999] implications)))))))
    (.:[1999..2000] .)))

;sentence 16 Span:2001..2139
;It can be concluded that the potential for drug-drug  interactions with
;esomeprazole is low, and similar to that reported for  omeprazole.
;[2044..2048]:substance:"drug"
;[2049..2053]:substance:"drug"
;[2073..2085]:substance:"esomeprazole"
;[2128..2138]:substance:"omeprazole"
(SENT
  (S
    (NP-SBJ-1
      (NP (PRP:[2001..2003] It))
      (SBAR-2 (-NONE-:[2003..2003] *ICH*)))
    (VP (MD:[2004..2007] can)
      (VP (VB:[2008..2010] be)
        (VP (VBN:[2011..2020] concluded)
          (NP-1 (-NONE-:[2020..2020] *))
          (SBAR-2 (IN:[2021..2025] that)
            (S
              (NP-SBJ
                (NP (DT:[2026..2029] the) (NN:[2030..2039] potential))
                (PP (IN:[2040..2043] for)
                  (NP
                    (NP
                      (NML (NN:[2044..2048] drug) (HYPH:[2048..2049] -)
                           (NN:[2049..2053] drug))
                      (NNS:[2055..2067] interactions))
                    (PP (IN:[2068..2072] with)
                      (NP (NN:[2073..2085] esomeprazole))))))
              (VP (VBZ:[2086..2088] is)
                (ADJP-PRD
                  (ADJP (JJ:[2089..2092] low))
                  (,:[2092..2093] ,) (CC:[2094..2097] and)
                  (ADJP (JJ:[2098..2105] similar)
                    (PP (TO:[2106..2108] to)
                      (NP
                        (NP (DT:[2109..2113] that))
                        (VP (VBN:[2114..2122] reported)
                          (NP (-NONE-:[2122..2122] *))
                          (PP (IN:[2123..2126] for)
                            (NP (NN:[2128..2138] omeprazole))))))))))))))
    (.:[2138..2139] .)))

;section 17 Span:2143..2161
;Publication Types:
(SEC
  (FRAG (NNP:[2143..2154] Publication) (NNP:[2155..2160] Types)
        (::[2160..2161] :)))

;section 18 Span:2167..2173
;Review
(SEC
  (FRAG (NNP:[2167..2173] Review)))

;section 19 Span:2179..2195
;Review, Tutorial
(SEC
  (FRAG (NNP:[2179..2185] Review) (,:[2185..2186] ,) (NNP:[2187..2195] Tutorial)))

;section 20 Span:2199..2244
;PMID: 11510629 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2199..2203] PMID) (::[2203..2204] :) (CD:[2205..2213] 11510629)
        (-LRB-:[2214..2215] -LSB-) (NNP:[2215..2221] PubMed)
        (HYPH:[2222..2223] -) (NN:[2224..2231] indexed) (IN:[2232..2235] for)
        (NNP:[2236..2243] MEDLINE) (-RRB-:[2243..2244] -RSB-)))
